Cerilliant Corporation (www.cerilliant.com) is an Austin, Texas-based specialty chemicals company that develops and manufactures high quality analytical reference standards and reagents used in medical, forensic, toxicology, environmental, pharmaceutical and other test laboratories. Cerilliant has developed a worldwide reputation as a leading provider of analytical reference standards and is well known for its visionary approach to serving a broad range of test laboratories with a continually expanding line of innovative new products.
Cerilliant participates in the $600+ million global analytical reference standards market. Cerilliant has established itself as an innovator and leader within its niche, with commanding market shares in the forensic/toxicology and medical/clinical laboratory markets. Sigma-Aldrich, the world’s largest manufacturer of analytical reference standards, generates over $2 billion in net sales annually across all of its business units. The acquisition of Cerilliant strengthens Sigma-Aldrich’s analytical chemistry product portfolio.
Prestwick Partners initiated this transaction and acted as exclusive financial advisor to Cerilliant (Austin, Texas) and Argenta Partners (f/k/a Lynch Investment Company) (Dallas, Texas). Prestwick Partners designed an M&A process, prepared marketing materials, evaluated acquisition proposals and negotiated the transaction with Sigma-Aldrich (NASDAQ: SIAL), a St. Louis, Missouri-based life sciences and high-technology company. The M&A process took just over three months from initial contact to closing. The sale of Cerilliant was Prestwick Partners third successful divestiture of an Argenta Partners’ portfolio company.